5073 Calcium ATPase transmembrane domain-related
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Homogeneous metal compounds | 17 | 12.1 | 1.41× | q = 0.11 | |
| Homogeneous non-metal compounds | 1 | 5.3 | 0.19× | q = 0.07 | |
| Nucleosides, nucleotides, and analogues | 0 | 6.8 | 0 | q = 1.3e-3 | |
| Lipids and lipid-like molecules | 19 | 2.7 | 6.92× | not tested | |
| Phenylpropanoids and polyketides | 2 | 0.5 | 3.90× | not tested | |
| Mixed metal/non-metal compounds | 1 | 0.5 | 1.93× | not tested | |
| Organic oxygen compounds | 7 | 4.9 | 1.43× | not tested | |
| Organic nitrogen compounds | 1 | 0.8 | 1.27× | not tested | |
| Organoheterocyclic compounds | 4 | 3.8 | 1.05× | not tested | |
| Benzenoids | 1 | 1.8 | 0.56× | not tested | |
| Organic acids and derivatives | 2 | 3.8 | 0.52× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB04540 | CLR | Cholesterol | 103 |
| DB03690 | PCW | (Z,Z)-4-Hydroxy-N,N,N-Trimethyl-10-Oxo-7-[(1-Oxo-9-Octadecenyl)Oxy]-3,5,9-Trioxa-4-Phosphaheptacos-18-En-1-Aminium-4-Oxide | 76 |
| DB01092 | OBN | Ouabain | 15 |
| DB07604 | CZA | (6AR,11AS,11BR)-10-ACETYL-9-HYDROXY-7,7-DIMETHYL-2,6,6A,7,11A,11B-HEXAHYDRO-11H-PYRROLO[1',2':2,3]ISOINDOLO[4,5,6-CD]INDOL-11-ONE | 13 |
| DB03429 | CDL | Tetrastearoyl cardiolipin | 9 |
| DB00390 | DGX | Digoxin | 5 |
| DB18573 | 17F | 1,2-Dioleoyl-sn-glycero-3-phospho-L-serine | 4 |
| DB00141 | NAG | N-Acetylglucosamine | 3 |
| DB01396 | F9R | Digitoxin | 3 |
| DB04638 | BHQ | 2,5-di-tert-butylhydroquinone | 3 |
| DB00228 | — | — | 2 |
| DB06157 | — | — | 2 |
| DB12350 | E4R | Rostafuroxin | 2 |
| DB00144 | P5S | Phosphatidyl serine | 1 |
| DB00213 | — | — | 1 |
| DB00338 | — | — | 1 |
| DB00448 | — | — | 1 |
| DB00511 | — | — | 1 |
| DB00736 | — | — | 1 |
| DB00753 | — | Isoflurane | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| CLR | CHOLESTEROL | 122 |
| MGmetal | MAGNESIUM ION | 96 |
| PCW | 1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOCHOLINE | 93 |
| NAmetal | SODIUM ION | 70 |
| Kmetal | POTASSIUM ION | 61 |
| CAmetal | CALCIUM ION | 38 |
| TG1 | OCTANOIC ACID [3S-[3ALPHA, 3ABETA, 4ALPHA, 6BETA, 6ABETA, 7BETA, 8ALPHA(Z),9BALPHA]]-6-(ACETYLOXY)-2,3,-3A,4,5,6,6A,7,8,9B-DECAHYDRO-3,3A-DIHYDROXY-3,6,9-TRIMETHYL-8-[(2-METHYL-1-OXO-2-BUTENYL)OXY]-2-OXO-4-(1-OXOBUTOXY)-AZULENO[4,5-B]FURAN-7-YL ESTER | 38 |
| PC1 | 1,2-DIACYL-SN-GLYCERO-3-PHOSPHOCHOLINE | 21 |
| RBmetal | RUBIDIUM ION | 21 |
| PTY | PHOSPHATIDYLETHANOLAMINE | 20 |
| BEF | BERYLLIUM TRIFLUORIDE ION | 18 |
| ALF | TETRAFLUOROALUMINATE ION | 16 |
| TLmetal | THALLIUM (I) ION | 14 |
| OBN | OUABAIN | 13 |
| POV | (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate | 13 |
| CZA | (6AR,11AS,11BR)-10-ACETYL-9-HYDROXY-7,7-DIMETHYL-2,6,6A,7,11A,11B-HEXAHYDRO-11H-PYRROLO[1',2':2,3]ISOINDOLO[4,5,6-CD]INDOL-11-ONE | 12 |
| Y01 | CHOLESTEROL HEMISUCCINATE | 12 |
| CE1 | O-DODECANYL OCTAETHYLENE GLYCOL | 11 |
| SPM | SPERMINE | 11 |
| CDL | CARDIOLIPIN | 10 |